Leukemia & Lymphoma

Novel drug safe for patients with leukemia

Novel drug safe for patients with leukemia

By

Results of a phase I clinical trial showed that a new drug targeting mitochondrial function in human cancer cells was safe and showed some efficacy in a heavily pretreated cohort of patients.

Managing follicular lymphoma

Managing follicular lymphoma

Changes in how follicular lymphoma is managed have led to substantial improvement in prognosis and over all survival for patients with the disease.

Study explores reasons for significant variations in blood cancer survival across Europe

Study explores reasons for significant variations in blood cancer survival across Europe

The EUROCARE study, the largest population-based study of survival in European blood cancer patients to date, analyzed data from 30 cancer registries, involving all patients with cancer diagnoses in 20 European countries.

US Food and Drug Administration fast-tracks novel leukemia therapy

US Food and Drug Administration fast-tracks novel leukemia therapy

An experimental immunotherapy agent was placed on the US Food and Drug Administration's fast track to market approval after overwhelmingly positive results were seen in patients with leukemia. In early trials, 89% of patients who received the personalized immunotherapy known as CTL019 saw their cancers disappear.

Leukemia gene leads to potential target for triple-negative breast cancer treatment

Leukemia gene leads to potential target for triple-negative breast cancer treatment

Scientists have discovered that a gene previously linked to leukaemia could provide an urgently needed target for the development of drugs to treat patients with 'triple negative' breast cancer.

Restoring gene function reverses cancer in common childhood leukemia

Restoring gene function reverses cancer in common childhood leukemia

Researchers in Melbourne, Australia, have shown that switching off a gene called Pax5 could cause a type of leukemia, and restoring its function could cure the disease.

Nearly one-quarter of children in remission from ALL miss doses of maintenance medication

Nearly one-quarter of children in remission from ALL miss doses of maintenance medication

Children in remission from acute lymphocytic leukemia (ALL) must take 6-mercaptopurine (6MP) for 2 years to prevent disease reemergence; however, a study shows that an estimated 25% of children in remission are not taking this essential maintenance medication at least 90% of the time, tripling their relapse risk.

For patients with AIDS-related lymphomas, identification of CNS involvement at diagnosis does not affect overall survival

For patients with AIDS-related lymphomas, identification of CNS involvement at diagnosis does not affect overall survival

Patients with AIDS-related lymphomas may face an increased risk of CNSi compared to other lymphomas. Researchers report that CNSi - identified at the time of an ARL diagnosis - does not appear to have an impact on overall survival. The vast majority of patients have stage IV disease at the time of presentation.

Sign Up for Free e-newsletters

Regimen and Drug Listings

GET FULL LISTINGS OF TREATMENT Regimens and Drug INFORMATION

Bone Cancer Regimens Drugs
Brain Cancer Regimens Drugs
Breast Cancer Regimens Drugs
Endocrine Cancer Regimens Drugs
Gastrointestinal Cancer Regimens Drugs
Genitourinary Cancer Regimens Drugs
Gynecologic Cancer Regimens Drugs
Head and Neck Cancer Regimens Drugs
Hematologic Cancer Regimens Drugs
Lung Cancer Regimens Drugs
Other Cancers Regimens
Rare Cancers Regimens
Skin Cancer Regimens Drugs